We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
Read MoreHide Full Article
Key Takeaways
CGON targets a fourth-quarter 2026 BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC.
CG Oncology reported encouraging phase II efficacy with no grade 3 treatment-related adverse events.
CGON expects multiple 2026 data readouts and has sufficient cash to support operations through 2029.
Shares of CG Oncology (CGON - Free Report) have risen 12% over the past three months against the industry’s 1.1% decline, primarily driven by growing investor optimism around its lead bladder cancer therapy, cretostimogene grenadenorepvec, accelerating regulatory momentum and a robust balance sheet.
CGON’s pipeline is centered on cretostimogene, an investigational, intravesically delivered oncolytic immunotherapy that is being studied as a monotherapy and in combination regimens across several mid- and late-stage studies targeting bladder cancer. The candidate has shown strong clinical progress in multiple studies previously.
The company continues to make steady progress toward its first biologics license application (BLA), with management expecting to complete the BLA submission for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS), with or without Ta/T1 disease in the fourth quarter of 2026, following alignment discussions with the FDA. This regulatory progress has strengthened investor confidence in CG Oncology's transition toward becoming a commercial-stage biotechnology company.
Positive Phase II Data Strengthen CGON’s Growth Outlook
CGON announced positive early data in mid-May from the phase II CORE-008 Cohort CX study evaluating cretostimogene in combination with gemcitabine in patients with high-risk NMIBC who were either BCG-exposed or BCG-unresponsive. Per management, Cohort CX was designed to evaluate whether combining cretostimogene with gemcitabine can further improve the strong clinical benefits seen with cretostimogene monotherapy.
The study demonstrated encouraging efficacy, with high-grade event-free survival of 96.0% at three months and 89.5% at six months, along with complete response rates of up to 92.3% in patients with CIS. Notably, similar efficacy was observed with both concurrent and sequential treatment schedules. The therapy was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related deaths, supporting its potential as a safe and effective bladder-sparing treatment option for high-risk NMIBC patients.
Multiple Clinical Catalysts Expected in 2026
CG Oncology has several important clinical milestones scheduled for 2026. The company expects top-line data from the phase III PIVOT-006 study, which is evaluating cretostimogene monotherapy as an adjuvant treatment for patients with intermediate-risk NMIBC. The study's primary endpoint is recurrence-free survival (RFS), with additional secondary endpoints including RFS at predefined time points and progression-free survival.
The company also plans to report durability data from the late-stage BOND-003 study cohorts C and P and mid-stage CORE-008 cohort A studies later in 2026. These upcoming readouts are expected to strengthen the long-term commercial potential of cretostimogene across multiple bladder cancer settings.
CGON’s Strong Cash Position Reduces Financing Risk
From a financial standpoint, CG Oncology remains well funded to execute its clinical and regulatory strategy. As of March 31, 2026, the company reported $1.1 billion in cash, cash equivalents and marketable securities, significantly higher than in the previous quarter, following a successful capital raise. Management expects this strong liquidity position to fund operations through 2029, providing ample financial flexibility to support late-stage clinical development, regulatory activities and future commercialization without requiring near-term financing.
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.47. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 24.9% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, loss per share estimates for Amarin Corporation have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 6.7% year to date.
Amarin Corporation’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.10. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.14. LQDA shares have gained 126% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
Key Takeaways
Shares of CG Oncology (CGON - Free Report) have risen 12% over the past three months against the industry’s 1.1% decline, primarily driven by growing investor optimism around its lead bladder cancer therapy, cretostimogene grenadenorepvec, accelerating regulatory momentum and a robust balance sheet.
Image Source: Zacks Investment Research
CGON’s Cretostimogene Advances Toward Commercialization
CGON’s pipeline is centered on cretostimogene, an investigational, intravesically delivered oncolytic immunotherapy that is being studied as a monotherapy and in combination regimens across several mid- and late-stage studies targeting bladder cancer. The candidate has shown strong clinical progress in multiple studies previously.
The company continues to make steady progress toward its first biologics license application (BLA), with management expecting to complete the BLA submission for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS), with or without Ta/T1 disease in the fourth quarter of 2026, following alignment discussions with the FDA. This regulatory progress has strengthened investor confidence in CG Oncology's transition toward becoming a commercial-stage biotechnology company.
Positive Phase II Data Strengthen CGON’s Growth Outlook
CGON announced positive early data in mid-May from the phase II CORE-008 Cohort CX study evaluating cretostimogene in combination with gemcitabine in patients with high-risk NMIBC who were either BCG-exposed or BCG-unresponsive. Per management, Cohort CX was designed to evaluate whether combining cretostimogene with gemcitabine can further improve the strong clinical benefits seen with cretostimogene monotherapy.
The study demonstrated encouraging efficacy, with high-grade event-free survival of 96.0% at three months and 89.5% at six months, along with complete response rates of up to 92.3% in patients with CIS. Notably, similar efficacy was observed with both concurrent and sequential treatment schedules. The therapy was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related deaths, supporting its potential as a safe and effective bladder-sparing treatment option for high-risk NMIBC patients.
Multiple Clinical Catalysts Expected in 2026
CG Oncology has several important clinical milestones scheduled for 2026. The company expects top-line data from the phase III PIVOT-006 study, which is evaluating cretostimogene monotherapy as an adjuvant treatment for patients with intermediate-risk NMIBC. The study's primary endpoint is recurrence-free survival (RFS), with additional secondary endpoints including RFS at predefined time points and progression-free survival.
The company also plans to report durability data from the late-stage BOND-003 study cohorts C and P and mid-stage CORE-008 cohort A studies later in 2026. These upcoming readouts are expected to strengthen the long-term commercial potential of cretostimogene across multiple bladder cancer settings.
CGON’s Strong Cash Position Reduces Financing Risk
From a financial standpoint, CG Oncology remains well funded to execute its clinical and regulatory strategy. As of March 31, 2026, the company reported $1.1 billion in cash, cash equivalents and marketable securities, significantly higher than in the previous quarter, following a successful capital raise. Management expects this strong liquidity position to fund operations through 2029, providing ample financial flexibility to support late-stage clinical development, regulatory activities and future commercialization without requiring near-term financing.
CG Oncology, Inc. Price and Consensus
CG Oncology, Inc. price-consensus-chart | CG Oncology, Inc. Quote
CGON’s Zacks Rank & Stocks to Consider
CG Oncology currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) , Amarin Corporation (AMRN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.47. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 24.9% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, loss per share estimates for Amarin Corporation have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 6.7% year to date.
Amarin Corporation’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.10. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.14. LQDA shares have gained 126% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.